ArticleFrontiers in oncology2025

Case Report: Multimodal immunotherapeutic regimen (envafolimab + chemotherapy + radiotherapy) for four synchronous primary malignant neoplasms: a case report of 33-month survival and implications for tumor immunology.

Yadong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.